Company intelligence / Profile preview

Shaanxi Pharmaceutical Group

Xi'an, Shaanxi, China

Ownership: Private
Development stage: Other

Overview

Shaanxi Pharmaceutical Holding Group (including the subsidiary Shaanxi Medicine Holding Group Biological Products) has commercialized and approved vaccines for tuberculosis (including BCG-based products) in China, with a historic track record and consistent regulatory approvals for their products[4]. Shaanxi Hanjiang Pharmaceutical Group is a leading API and intermediate manufacturer, supplying regulatory API and bulk finished ingredients including anthelmintics and hormones[1][12].

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologicLive attenuated vaccineProphylactic vaccine
Industry: Biotech

Beyond the preview

Go deeper on Shaanxi Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shaanxi Pharmaceutical Group.

Explore the full profile